Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin in Advanced Solid Tumors (EV-202)
NCT04225117Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Mar 2020
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of enfortumab vedotin in solid tumor (9 cohorts), sponsored by Astellas Pharma. Primary endpoint: Confirmed Overall Response Rate up to 12.85 months. Started Mar 2020; status: active, not recruiting.
02
Drugs
enfortumab vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04225117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225117.